KIAA1586

Summary

KIAA1586 (HGNC:21360) is a protein-coding gene on chromosome 6p12.1, encoding E3 SUMO-protein ligase KIAA1586 (Q9HCI6). E3 SUMO-protein ligase; facilitates UBE2I/UBC9-mediated SUMO2 modification of target proteins.

Enables SUMO ligase activity. Involved in protein sumoylation.

Source: NCBI Gene 57691 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 117 total — 2 likely-pathogenic
• Phenotypes (HPO): 1
• MANE Select transcript: NM_020931

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:21360
Approved symbol	KIAA1586
Name	KIAA1586
Location	6p12.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000168116
Ensembl biotype	protein_coding
Entrez	57691

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 4 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000370733, ENST00000488682, ENST00000545356, ENST00000928058, ENST00000928059

RefSeq mRNA: 4 — MANE Select: NM_020931 NM_001286274, NM_001286275, NM_001286276, NM_020931

CCDS: CCDS34480, CCDS69138

Canonical transcript exons

ENST00000370733 — 4 exons

Exon	Start	End
ENSE00001453480	57052686	57055225
ENSE00001453509	57046693	57046776
ENSE00003480440	57047313	57047396
ENSE00003687066	57050774	57050854

Expression profiles

Bgee: expression breadth ubiquitous, 200 present calls, max score 90.23.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 14.3017 / max 283.6481, expressed in 1761 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
68323	12.7715	1750
68322	0.8775	411
68320	0.4933	304
68321	0.1594	55

Top tissues by expression

242 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	90.23	gold quality
cortical plate	UBERON:0005343	89.37	gold quality
adrenal tissue	UBERON:0018303	89.23	gold quality
ganglionic eminence	UBERON:0004023	87.31	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	86.08	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	85.73	gold quality
ventricular zone	UBERON:0003053	84.53	gold quality
tendon	UBERON:0000043	84.17	gold quality
monocyte	CL:0000576	81.06	gold quality
bone marrow cell	CL:0002092	80.80	gold quality
stromal cell of endometrium	CL:0002255	80.63	gold quality
leukocyte	CL:0000738	80.44	gold quality
colonic epithelium	UBERON:0000397	79.24	gold quality
islet of Langerhans	UBERON:0000006	78.39	gold quality
right testis	UBERON:0004534	78.13	gold quality
left ovary	UBERON:0002119	77.99	gold quality
smooth muscle tissue	UBERON:0001135	77.28	gold quality
testis	UBERON:0000473	77.24	gold quality
left testis	UBERON:0004533	77.18	gold quality
ovary	UBERON:0000992	77.08	gold quality
prefrontal cortex	UBERON:0000451	76.44	gold quality
tendon of biceps brachii	UBERON:0008188	76.02	silver quality
right ovary	UBERON:0002118	75.98	gold quality
left adrenal gland	UBERON:0001234	75.94	gold quality
right adrenal gland cortex	UBERON:0035827	75.82	gold quality
left adrenal gland cortex	UBERON:0035825	75.73	gold quality
right adrenal gland	UBERON:0001233	75.53	gold quality
body of uterus	UBERON:0009853	75.30	gold quality
bone marrow	UBERON:0002371	75.24	gold quality
adrenal gland	UBERON:0002369	75.18	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.82

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): MYC

miRNA regulators (miRDB)

53 targeting KIAA1586, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488
HSA-MIR-548AP-5P	99.94	71.14	3489
HSA-MIR-548AQ-5P	99.94	71.34	3426
HSA-MIR-548AR-5P	99.94	71.28	3515
HSA-MIR-548AS-5P	99.94	71.22	3482
HSA-MIR-548AU-5P	99.94	71.24	3488
HSA-MIR-548AY-5P	99.94	71.23	3502
HSA-MIR-548B-5P	99.94	71.23	3502
HSA-MIR-548BB-5P	99.94	71.27	3509
HSA-MIR-548C-5P	99.94	71.24	3488
HSA-MIR-548D-5P	99.94	71.23	3502
HSA-MIR-548H-5P	99.94	71.24	3488
HSA-MIR-548I	99.94	71.25	3481
HSA-MIR-548J-5P	99.94	71.14	3489
HSA-MIR-548O-5P	99.94	71.24	3488
HSA-MIR-548W	99.94	71.24	3488
HSA-MIR-548Y	99.94	71.28	3514
HSA-MIR-9983-3P	99.94	71.48	3631

Cross-species orthologs

0 orthologs

Protein

Protein identifiers

E3 SUMO-protein ligase KIAA1586 — Q9HCI6 (reviewed: Q9HCI6)

Alternative names: E3 SUMO-protein transferase KIAA1586

All UniProt accessions (2): Q9HCI6, F5H2N6

UniProt curated annotations — full annotation on UniProt →

Function. E3 SUMO-protein ligase; facilitates UBE2I/UBC9-mediated SUMO2 modification of target proteins.

Subunit / interactions. Interacts with UBE2I/UBC9 and SUMO2.

Domain organisation. Binds UBE2I/UBC9 and two SUMO2 molecules via its N-terminus. The most N-terminal region interacts with the SUMO2 chain that is covalently bound to the UBE2I/UBC9 active site, while the second region interacts with another SUMO2 that is non-covalently associated with the same UBE2I/UBC9 chain.

Pathway. Protein modification; protein sumoylation.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9HCI6-1	1	yes
Q9HCI6-2	2

RefSeq proteins (4): NP_001273203, NP_001273204, NP_001273205, NP_065982* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR012337	RNaseH-like_sf	Homologous_superfamily

UniProt features (12 total): region of interest 4, cross-link 3, sequence variant 2, chain 1, short sequence motif 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9HCI6-F1	74.05	0.28

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (3): 85, 119, 125

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 82 (showing top): GOBP_PEPTIDYL_LYSINE_MODIFICATION, chr6p12, GOBP_PROTEIN_SUMOYLATION, GOBP_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, GARY_CD5_TARGETS_DN, DANG_BOUND_BY_MYC, GOMF_ACYLTRANSFERASE_ACTIVITY, GOMF_SUMO_TRANSFERASE_ACTIVITY, GOMF_AMINOACYLTRANSFERASE_ACTIVITY, GOMF_UBIQUITIN_LIKE_PROTEIN_LIGASE_ACTIVITY, WHITFIELD_CELL_CYCLE_G1_S, MARTENS_TRETINOIN_RESPONSE_DN, JOHNSTONE_PARVB_TARGETS_3_DN, GOMF_SUMO_LIGASE_ACTIVITY, CBX7_TARGET_GENES

GO Biological Process (1): protein sumoylation (GO:0016925)

GO Molecular Function (2): SUMO ligase activity (GO:0061665), transferase activity (GO:0016740)

GO Cellular Component (0):

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
peptidyl-lysine modification	1
protein modification by small protein conjugation	1
SUMO transferase activity	1
ubiquitin-like protein ligase activity	1
catalytic activity	1

Protein interactions and networks

STRING

362 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
KIAA1586	ZBED8	Q8IZ13	396
KIAA1586	OR1C1	Q15619	391
KIAA1586	OR4M2	Q8NGB6	359
KIAA1586	LCNL1	Q6ZST4	358
KIAA1586	FAM89B	Q8N5H3	358
KIAA1586	TTC33	Q6PID6	357
KIAA1586	CIMAP1D	Q3SX64	356
KIAA1586	RNF133	Q8WVZ7	352
KIAA1586	AIRIM	Q9NX04	351
KIAA1586	RNF148	Q8N7C7	351
KIAA1586	OR4N4	Q8N0Y3	349
KIAA1586	SIMC1	Q8NDZ2	348
KIAA1586	TOPORS	Q9NS56	336
KIAA1586	TASOR2	Q5VWN6	331
KIAA1586	TRIM27	P14373	318

IntAct

14 interactions, top by confidence:

A	B	Type	Score
NRBP1	TBC1D4	psi-mi:“MI:0914”(association)	0.530
ECE1	KIAA1586	psi-mi:“MI:0915”(physical association)	0.370
SPACA1	ESYT2	psi-mi:“MI:0914”(association)	0.350
RAMP2	GXYLT2	psi-mi:“MI:0914”(association)	0.350
CLEC2D	TMEM120B	psi-mi:“MI:0914”(association)	0.350
EFNA4	NBAS	psi-mi:“MI:0914”(association)	0.350
IGHD	POTEF	psi-mi:“MI:0914”(association)	0.350
TACSTD2	RIMOC1	psi-mi:“MI:0914”(association)	0.350
DGCR2	CCDC85C	psi-mi:“MI:0914”(association)	0.350
CYB5B	QSOX1	psi-mi:“MI:0914”(association)	0.350
KLRC2	CLGN	psi-mi:“MI:0914”(association)	0.350
KLRD1	PRORP	psi-mi:“MI:0914”(association)	0.350
P2RX2	C1QL1	psi-mi:“MI:0914”(association)	0.350

BioGRID (22): KIAA1586 (Affinity Capture-MS), KIAA1586 (Affinity Capture-MS), KIAA1586 (Affinity Capture-MS), KIAA1586 (Affinity Capture-MS), KIAA1586 (Biochemical Activity), KIAA1586 (Proximity Label-MS), KIAA1586 (Affinity Capture-MS), KIAA1586 (Affinity Capture-MS), KIAA1586 (Affinity Capture-MS), KIAA1586 (Affinity Capture-MS), KIAA1586 (Affinity Capture-MS), KIAA1586 (Affinity Capture-MS), KIAA1586 (Affinity Capture-MS), KIAA1586 (Affinity Capture-MS), KIAA1586 (Affinity Capture-MS)

ESM2 similar proteins: A4IFA3, A4Z943, A4Z944, A4Z945, B2RRL2, D3Z4R1, F1NQJ3, O43422, O60108, O60290, O96006, P08770, P0CF97, P12258, P16320, P34601, Q09772, Q0VBL1, Q17RP2, Q3EBC8, Q3YK19, Q49AG3, Q4R6P1, Q4W5G0, Q5SVZ6, Q5SXJ3, Q6EKJ0, Q6NT04, Q6R2W3, Q7L775, Q7M3K2, Q86UP8, Q8BUZ3, Q8IY51, Q8IZ13, Q8TBB0, Q8TCP9, Q8TDG4, Q8VEH5, Q95M72

Diamond homologs: Q8C0P7, Q9HCI6, Q9Y4E5

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

117 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	2
Uncertain significance	100
Likely benign	12
Benign	0

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
545337	NC_000006.12:g.(?57046622)(57088889_?)del	Likely pathogenic
545338	NC_000006.12:g.(?57046622)(57092420_?)del	Likely pathogenic

SpliceAI

625 predictions. Top by Δscore:

Variant	Effect	Δscore
6:57046777:G:GG	donor_gain	1.0000
6:57047392:TCAGT:T	donor_gain	1.0000
6:57047393:CAGT:C	donor_gain	1.0000
6:57047395:GT:G	donor_gain	1.0000
6:57047396:TGTAA:T	donor_loss	1.0000
6:57047397:G:GG	donor_gain	1.0000
6:57047397:GTAA:G	donor_loss	1.0000
6:57047398:T:A	donor_loss	1.0000
6:57047399:AAGTA:A	donor_loss	1.0000
6:57050769:TTTA:T	acceptor_loss	1.0000
6:57050770:TTA:T	acceptor_loss	1.0000
6:57050771:TA:T	acceptor_loss	1.0000
6:57050772:A:AG	acceptor_gain	1.0000
6:57050772:AG:A	acceptor_gain	1.0000
6:57050773:G:GA	acceptor_gain	1.0000
6:57050773:GG:G	acceptor_gain	1.0000
6:57050773:GGAA:G	acceptor_gain	1.0000
6:57050850:GTGAT:G	donor_gain	1.0000
6:57050851:TGAT:T	donor_gain	1.0000
6:57050852:GAT:G	donor_gain	1.0000
6:57050852:GATG:G	donor_gain	1.0000
6:57050853:AT:A	donor_gain	1.0000
6:57050853:ATG:A	donor_loss	1.0000
6:57050854:TG:T	donor_loss	1.0000
6:57050855:G:GG	donor_gain	1.0000
6:57050855:G:T	donor_loss	1.0000
6:57050856:T:G	donor_loss	1.0000
6:57052682:TCAG:T	acceptor_loss	1.0000
6:57052683:CAG:C	acceptor_loss	1.0000
6:57052684:A:AG	acceptor_gain	1.0000

AlphaMissense

5223 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:57052950:T:A	W151R	0.991
6:57052950:T:C	W151R	0.991
6:57052908:T:A	W137R	0.990
6:57052908:T:C	W137R	0.990
6:57053049:T:A	W184R	0.990
6:57053049:T:C	W184R	0.990
6:57053110:G:C	R204P	0.988
6:57052910:G:C	W137C	0.984
6:57052910:G:T	W137C	0.984
6:57053107:T:C	L203P	0.982
6:57052932:T:C	F145L	0.980
6:57052934:T:A	F145L	0.980
6:57052934:T:G	F145L	0.980
6:57053051:G:C	W184C	0.979
6:57053051:G:T	W184C	0.979
6:57053100:G:C	A201P	0.978
6:57052909:G:C	W137S	0.977
6:57052954:T:C	L152P	0.975
6:57052954:T:A	L152H	0.973
6:57052952:G:C	W151C	0.971
6:57052952:G:T	W151C	0.971
6:57053129:T:A	H210Q	0.969
6:57053129:T:G	H210Q	0.969
6:57053136:T:C	S213P	0.967
6:57052980:T:A	C161S	0.965
6:57052981:G:C	C161S	0.965
6:57053247:T:C	F250L	0.965
6:57053249:C:A	F250L	0.965
6:57053249:C:G	F250L	0.965
6:57052978:G:A	G160E	0.964

dbSNP variants (sampled 300 via entrez): RS1000117532 (6:57052024 G>A), RS1000326687 (6:57046464 G>A,C), RS1000614937 (6:57048551 T>C), RS1000898933 (6:57067185 T>A), RS1000983089 (6:57059731 C>T), RS1001108755 (6:57047039 C>T), RS1001650356 (6:57062798 C>G,T), RS1002016671 (6:57056610 C>A), RS1002153789 (6:57056337 G>A), RS1002185308 (6:57046531 A>T), RS1002320406 (6:57049780 T>C), RS1002340537 (6:57053801 A>C), RS1002683883 (6:57059613 A>C,G,T), RS1002785905 (6:57052543 A>G), RS1002931042 (6:57045247 C>A,G,T)

Disease associations

OMIM: gene `` | disease phenotypes: MIM:181500

GenCC curated gene-disease

Mondo (1): schizophrenia (MONDO:0005090)

Orphanet (1): NON RARE IN EUROPE: Schizophrenia (Orphanet:3140)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0100753	Schizophrenia

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

33 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases expression, increases expression	2
perfluorooctane sulfonic acid	decreases expression	2
aristolochic acid I	decreases expression	1
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
TAK-243	increases sumoylation	1
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
sodium arsenite	increases expression	1
butyraldehyde	decreases expression	1
resorcinol	increases expression	1
pentanal	decreases expression	1
ICG 001	decreases expression	1
abrine	increases expression	1
jinfukang	decreases expression	1
NSC 689534	affects binding, decreases expression	1
MT19c compound	increases expression	1
Resveratrol	increases expression, affects cotreatment	1
Vorinostat	increases expression	1
Air Pollutants	increases abundance, decreases expression	1
Benzo(a)pyrene	increases methylation	1
Copper	decreases expression, affects binding	1
Diethylstilbestrol	decreases expression	1
Endosulfan	decreases expression	1
Hydrogen Peroxide	decreases expression	1
Lead	affects expression	1
Plant Extracts	affects cotreatment, increases expression	1
Quercetin	decreases expression	1
Silver	decreases expression	1
Thimerosal	increases expression	1
Urethane	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00000374	PHASE4	COMPLETED	Treatment for First-Episode Schizophrenia
NCT00001656	PHASE4	COMPLETED	Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
NCT00007774	PHASE4	COMPLETED	To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia
NCT00014001	PHASE4	COMPLETED	CATIE- Schizophrenia Trial
NCT00018668	PHASE4	COMPLETED	Antipsychotic Response in Schizophrenia
NCT00034801	PHASE4	COMPLETED	Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
NCT00034905	PHASE4	COMPLETED	A Comparison of Seroquel vs. Risperidone in Schizophrenia
NCT00036088	PHASE4	COMPLETED	Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
NCT00044187	PHASE4	COMPLETED	The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
NCT00044655	PHASE4	COMPLETED	Switching Medication to Treat Schizophrenia
NCT00048828	PHASE4	COMPLETED	Treating Drug-Resistant Childhood Schizophrenia
NCT00053703	PHASE4	COMPLETED	Treatment of Early Onset Schizophrenia Spectrum Disorders (TEOSS)
NCT00056498	PHASE4	COMPLETED	Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine
NCT00061802	PHASE4	COMPLETED	Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
NCT00080327	PHASE4	COMPLETED	Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
NCT00088049	PHASE4	COMPLETED	Study of Olanzapine vs. Aripiprazole in the Treatment of Schizophrenia
NCT00090012	PHASE4	COMPLETED	Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
NCT00100776	PHASE4	COMPLETED	Efficacy of High Dose Olanzapine for the Treatment of Schizophrenia and Schizoaffective Disorder
NCT00103571	PHASE4	COMPLETED	Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
NCT00108368	PHASE4	COMPLETED	The Effects of Risperidone and Olanzapine on Thinking
NCT00114595	PHASE4	COMPLETED	Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
NCT00130923	PHASE4	COMPLETED	Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
NCT00137020	PHASE4	COMPLETED	Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
NCT00140166	PHASE4	COMPLETED	Treatment of Acute Schizophrenia With Vitamin Therapy
NCT00145847	PHASE4	COMPLETED	Naltrexone Treatment of Alcohol Abuse in Schizophrenia
NCT00148564	PHASE4	COMPLETED	Energy Homeostasis Under Treatment With Atypical Antipsychotics
NCT00156715	PHASE4	COMPLETED	Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
NCT00158223	PHASE4	COMPLETED	Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia
NCT00159081	PHASE4	COMPLETED	One Year Drug Treatment in First-Episode Schizophrenia
NCT00159120	PHASE4	COMPLETED	Maintenance Treatment vs. Stepwise Drug Discontinuation in First-Episode Schizophrenia
NCT00159133	PHASE4	COMPLETED	Prodrome-Based Early Intervention With Antipsychotics vs. Benzodiazepines in First-Episode Schizophrenia
NCT00159757	PHASE4	TERMINATED	12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
NCT00167817	PHASE4	COMPLETED	Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study
NCT00169026	PHASE4	TERMINATED	Alcoholism and Schizophrenia: Effects of Clozapine
NCT00169039	PHASE4	TERMINATED	Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
NCT00169065	PHASE4	COMPLETED	Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
NCT00169091	PHASE4	TERMINATED	Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia
NCT00176423	PHASE4	COMPLETED	Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia
NCT00176436	PHASE4	COMPLETED	Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients
NCT00177008	PHASE4	COMPLETED	Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety